Richard C. Reichman

9.6k total citations · 2 hit papers
116 papers, 7.4k citations indexed

About

Richard C. Reichman is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Richard C. Reichman has authored 116 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Epidemiology, 58 papers in Infectious Diseases and 49 papers in Virology. Recurrent topics in Richard C. Reichman's work include HIV Research and Treatment (46 papers), HIV/AIDS drug development and treatment (45 papers) and Cervical Cancer and HPV Research (25 papers). Richard C. Reichman is often cited by papers focused on HIV Research and Treatment (46 papers), HIV/AIDS drug development and treatment (45 papers) and Cervical Cancer and HPV Research (25 papers). Richard C. Reichman collaborates with scholars based in United States, France and United Kingdom. Richard C. Reichman's co-authors include William Bonnez, Robert C. Rose, Raphael Dolin, Thomas C. Merigan, Lisa M. Demeter, Carla Pettinelli, Lawrence Corey, Margaret A. Fischl, Fred Valentine and H P Madore and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Richard C. Reichman

116 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection

1990 951 citations Richard C. Reichman, Robert L. Murphy et al. New England Journal of Medicine profile →
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine

1996 600 citations Ann C. Collier, Robert W. Coombs et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard C. Reichman United States	39	4.1k	3.3k	3.2k	889	679	116	7.4k
Michael S. Gottlieb United States	23	4.1k 1.0×	3.3k 1.0×	3.4k 1.1×	1.6k 1.8×	615 0.9×	41	8.3k
Donna Mildvan United States	45	5.3k 1.3×	3.7k 1.1×	3.9k 1.2×	1.5k 1.6×	583 0.9×	130	9.6k
Michael H. Grieco United States	28	3.8k 0.9×	2.3k 0.7×	2.6k 0.8×	902 1.0×	589 0.9×	87	6.7k
Yvonne J. Bryson United States	41	2.8k 0.7×	2.7k 0.8×	2.8k 0.9×	1.5k 1.7×	514 0.8×	143	6.3k
Gunnel Biberfeld Sweden	50	3.4k 0.8×	4.0k 1.2×	2.9k 0.9×	2.4k 2.7×	854 1.3×	275	8.2k
Jeffrey Chodakewitz United States	17	4.2k 1.0×	4.0k 1.2×	1.3k 0.4×	880 1.0×	658 1.0×	24	6.2k
Judith Falloon United States	41	3.3k 0.8×	3.4k 1.0×	2.1k 0.7×	1.8k 2.1×	747 1.1×	91	6.7k
John M. Leedom United States	29	3.9k 0.9×	2.2k 0.7×	3.0k 0.9×	495 0.6×	575 0.8×	75	6.3k
Raphael Dolin United States	45	4.4k 1.1×	2.2k 0.7×	3.7k 1.2×	1.3k 1.4×	1.1k 1.6×	152	8.5k
Rob Schuurman Netherlands	48	5.0k 1.2×	3.7k 1.1×	3.1k 1.0×	572 0.6×	608 0.9×	163	7.8k

Countries citing papers authored by Richard C. Reichman

Since Specialization

Citations

This map shows the geographic impact of Richard C. Reichman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Reichman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Reichman more than expected).

Fields of papers citing papers by Richard C. Reichman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Reichman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Reichman. The network helps show where Richard C. Reichman may publish in the future.

Co-authorship network of co-authors of Richard C. Reichman

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Reichman. A scholar is included among the top collaborators of Richard C. Reichman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Reichman. Richard C. Reichman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gulick, Roy M., Zhaohui Su, Charles Flexner, et al.. (2007). Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211. The Journal of Infectious Diseases. 196(2). 304–312. 195 indexed citations

Okusanya, Ólanrewaju O., Alan Forrest, Robin DiFrancesco, et al.. (2007). Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrobial Agents and Chemotherapy. 51(5). 1822–1826. 20 indexed citations

DiFrancesco, Robin, Barry S. Zingman, Richard C. Reichman, et al.. (2007). Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease Inhibitors: Validation and Application. Therapeutic Drug Monitoring. 29(1). 103–109. 19 indexed citations

Ma, Qing, Alan Forrest, Susan L. Rosenkranz, et al.. (2007). Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharmaceutics & Drug Disposition. 29(2). 91–101. 6 indexed citations

Gulick, Roy M., Heather J. Ribaudo, Cecilia M. Shikuma, et al.. (2004). Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. New England Journal of Medicine. 350(18). 1850–1861. 396 indexed citations

Chen, Huiyuan, Richard C. Reichman, Michael C. Keefer, Michael P. McDermott, & Xia Jin. (2004). Establishment of an alternative intracellular cytokine staining assay for HIV/AIDS clinical studies. Journal of Virological Methods. 123(2). 131–140. 4 indexed citations

Benson, Constance A., Paige L. Williams, David L. Cohn, et al.. (2000). Clarithromycin or Rifabutin Alone or in Combination for Primary Prophylaxis ofMycobacterium aviumComplex Disease in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 181(4). 1289–1297. 62 indexed citations

Luque, Amneris E., Lisa M. Demeter, & Richard C. Reichman. (1999). Association of Human Papillomavirus Infection and Disease with Magnitude of Human Immunodeficiency Virus Type 1 (HIV‐1) RNA Plasma Level among Women with HIV‐1 Infection. The Journal of Infectious Diseases. 179(6). 1405–1409. 33 indexed citations

Demeter, Lisa M., Gene D. Morse, Peter Gerondelis, et al.. (1997). HIV-1 Drug Susceptibilities and Reverse Transcriptase Mutations in Patients Receiving Combination Therapy with Didanosine and Delavirdine. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14(2). 136–144. 36 indexed citations

10.

Collier, Ann C., Robert W. Coombs, David Schoenfeld, et al.. (1996). Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. New England Journal of Medicine. 334(16). 1011–1018. 600 indexed citations breakdown →

11.

Frenkel, Lisa M., Larry E. Wagner, Lisa M. Demeter, et al.. (1995). Effects of Zidovudine Use During Pregnancy on Resistance and Vertical Transmission of Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases. 20(5). 1321–1326. 78 indexed citations

12.

Demeter, Lisa M., et al.. (1995). Development of Zidovudine Resistance Mutations in Patients Receiving Prolonged Didanosine Monotherapy. The Journal of Infectious Diseases. 172(6). 1480–1485. 32 indexed citations

13.

Japour, Anthony J., Jean Marie Arduino, Hammer Sm, et al.. (1994). Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrobial Agents and Chemotherapy. 38(2). 307–314. 53 indexed citations

14.

Daher, N, M. C. Keefer, Richard C. Reichman, Raphael Dolin, & Norbert J. Roberts. (1993). Persisting Human Immunodeficiency Virus Type 1 gp160-Specific Human T Lymphocyte Responses Including CD8+ Cytotoxic Activity after Receipt of Envelope Vaccines. The Journal of Infectious Diseases. 168(2). 306–313. 33 indexed citations

15.

Clive, D., Lawrence Corey, Richard C. Reichman, L. Gray Davis, & John Hozier. (1991). A Double-Blind, Placebo-Controlled Cytogenetic Study of Oral Acyclovir in Patients with Recurrent Genital Herpes. The Journal of Infectious Diseases. 164(4). 753–757. 8 indexed citations

16.

Reichman, Richard C., John P. Micha, Phillip K. Weck, et al.. (1988). Interferon alpha-n1 (wellferon) for refractory genital warts: Efficacy and tolerance of low dose systemic therapy. Antiviral Research. 10(1-3). 41–57. 22 indexed citations

17.

Reichman, Richard C., Gary J. Badger, Grégory Mertz, et al.. (1984). Treatment of Recurrent Genital Herpes Simplex Infections with Oral Acyclovir. A Controlled Trial. Obstetrical & Gynecological Survey. 39(9). 595–596. 3 indexed citations

18.

Wolinsky, Steven M., et al.. (1984). Comparative Rates of Sexually Transmitted Diseases among Heterosexual Men, Homosexual Men, and Heterosexual Womend. Sexually Transmitted Diseases. 11(4). 271–274. 16 indexed citations

19.

Reichman, Richard C., et al.. (1977). Cell-Mediated Cytotoxicity in Recurrent Herpes Simplex Virus Infections in Man. Experimental Biology and Medicine. 155(4). 571–576. 17 indexed citations

20.

Dolin, Raphael, Richard C. Reichman, & A S Fauci. (1976). Lymphocyte populations in acute viral gastroenteritis. Infection and Immunity. 14(2). 422–428. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact